Indian Science Technology and Engineering facilities Map
 
Preivious Next  

  Digital Catalogue for Technology and Products Development


   Technology and Product Development

    Basic Information

Technology developed: A Single-dose Nanovaccine for Shigellosis and Process for Synthesis Thereof (TP19765953025)
Category:
Details of Inventor(s):
Inventor Institution/Organization/Company Department Designation
Dhirendra S. Katti IIT Kanpur BSBE Professor
Namrata Baruah IIT Kanpur BSBE Ph.D. Student
Technical Application Area: Other
If 'Other', please specify:
Biomedical Engineering
Please give more details of new technical application area:
Organization(s):
Indian Institute of Technology (IIT) Kanpur
Affiliated Ministry: Ministry of Education
Type of technology development: Indigenous
Does the technology help in replacing any import items currently
procured from outside India?
Yes
Does the technology have export potential? Yes
Category of Technology developed: Immediate Deployment
Stage of Development: Field Test
Please describe in detail including the TRL Level:
Field test is being carried out

    Abstract:

Applications: Shigellosis is a diarrheal disease caused by a group of bacteria called Shigella that was responsible for the death of two lakh people in 2016. Shigella strains have become antibiotic resistant and unfortunately, no commercial vaccines are available till date. An ideal Shigella vaccine would be one that provides protection against all species of Shigella. Herein, we have developed a single dose intranasal nanovaccine against Shigella made of PLGA ratio of 50 50 encapsulating a conserved, previously stabilized IpaC protein of S. dysenteriae 1 origin (100 per cent cross protection against S. flexneri 2a, one of the most common serotypes in circulation, when administered for 3 times, in our previous claim). Nanovaccines, due to the property of sustained release minimizes the frequency of dosage or hospital visit. The developed nanovaccine requires a single antigen and a single step of preparation and could provide around 67 per cent rotection against greater lethal challenge of Sf2a in BALB or c mice in a single dose. Since, the current innovation is a simple, non-invasive, single dose, intranasal nanovaccine with greater shelf life, we expect it to be amenable for mass production and immunization
Advantages: Single dose intranasal Shigella nanovaccine having application in Production of cost effective, single antigen pan Shigella vaccine. Nasal drop formulation. Ease of manufacturing can be further increased by making it a spraybased formulation The nanovaccine can be lyophilized leading to increased durability. Mass production and immunization.

    Technology Inputs:

Imported Equipment/Spare Parts:
Equipment/Spare Parts Year ITC-HS Code
NA
Indigenous Equipment/Spare Parts:
Equipment/Spare Parts Year ITC-HS Code
NA
Imported Raw Materials:
Raw Materials Year ITC-HS Code
NA
Indigenous Raw Materials:
Raw Materials Year ITC-HS Code
NA
Existing R&D Facilities used:
Facilities Year ITC-HS Code
NA

   Patents & Publications:

Patents:
Filed Patents (No.) Granted Patents (No.) Year
1 0 NA
Publications:
Submitted (No.) Published (No.) Year
0 1 NA

    Commercialization Potential:

Who are the Potential Licensees? GlaxoSmithKline, Sanofi Aventis, Pfizer, Novartis, Serum Institute of India, Merck, Hilleman LaboratoriesGlaxoSmithKline, Sanofi Aventis, Pfizer, Novartis, Serum Institute of India, Merck, Hilleman Laboratories
What commercially available products address
the same problem?
Company Product Problem Addressed
Would you like to develop this invention further with
corporate research support?
Yes
Would you be interested in participating in cluster based
programs for commercialization research or business
planning for your invention?
Yes
      Submitted by: J.G. Rao Date of Submission: 8-3-2022



Chat Room      Write Review     Talk to Experts


THE VISION
THE MISSION
ABOUT I-STEM
It has always been the basic tenet of the Government of India, in generously funding R&D efforts at academic institutions over the years, that facilities established through such support be made available to those needing them and qualified to make use of them for their own research work
read more >>

However, this was never easy or straightforward for, among other reasons, there was no ready source of information of what facility was available and where. Thanks to the Web, it is much easier today to have a national and regional “inventory of resources”, so as to match users with the resources they need, and to do all this in an efficient and transparent manner.

This can lead to a leap in R&D productivity and greatly enhance the effectiveness of public investment. This is the motivation behind I-STEM.
read less <<
Visitor Hit Counter
Hosted at Indian Institute of Science
Copyright © 2024 I-STEM. All rights reserved.
Audited by: STQC Bengaluru.